Key Takeaways
- • Healthcare services private equity dealmaking reached 747 transactions in 2025, a 9.6% year-over-year increase, though aggregate deal value declined 1.6% due to a meaningful Q4 pause and fewer closings.
- • Physician practice management (PPM) deal count fell 18% in 2025, with steep pullbacks in gastroenterology, fertility, and ENT subspecialties, while skilled nursing facilities, specialty pharmacy, hospitals and health systems, and intellectual and developmental disability practices led growth.
- • PPM exit count surged 57.1% in 2025, signaling early recovery potential for transaction volume in 2026 as sponsors reposition capital.
- • State-level regulatory friction in California and other jurisdictions is reshaping PPM transaction structuring, while uncertainty around 2026 premium subsidies delayed deal closures in Q4.
- • Sponsors face divergent competitive conditions by subsector: those pursuing oncology, musculoskeletal, and ambulatory surgical centers encounter different market dynamics than those still targeting dermatology and gastroenterology platforms.
Summary
Healthcare services private equity activity in 2025 presented a paradoxical picture of volume growth masking underlying market strain. Deal count increased 9.6% year-over-year to 747 transactions—marking recovery from a 2024 bottom—yet total deal value declined 1.6%, reflecting a significant Q4 pullback and fewer successful closings. This divergence suggests market consolidation around winners and losers rather than broad-based momentum.
Subsector performance diverged sharply. Physician practice management experienced the steepest headwinds, with deal count collapsing 18% as gastroenterology, fertility, and ENT practices faced steep valuations and limited buyer appetite. Conversely, skilled nursing facilities and specialty pharmacy drove growth, indicating sponsor focus on defensive, recurring-revenue healthcare services. This dispersion reveals that healthcare PE dealmaking in 2026 will be defined less by where capital remains active and more by which subsectors are entering their next consolidation cycle.
Two specific forces decelerated Q4 activity. State-level regulatory friction—particularly in California—is fundamentally reshaping how PPM transactions structure operations and ownership, adding complexity and legal uncertainty to deals. Simultaneously, uncertainty surrounding 2026 premium subsidies created deal timing risk, causing sponsors to delay closures pending clarity. These headwinds are temporary rather than structural.
A critical recovery signal emerged: PPM exit count jumped 57.1% in 2025, suggesting sponsors are actively harvesting mature positions and repositioning capital. Combined with subsector-level divergence, this exit activity indicates that sponsor pipelines in oncology, musculoskeletal, and ambulatory surgical centers operate in fundamentally different competitive conditions than those pursuing dermatology and gastroenterology platforms. The 2026 environment will reward selectivity and regulatory nimbleness over broad-brush consolidation strategies.
Subsector performance diverged sharply. Physician practice management experienced the steepest headwinds, with deal count collapsing 18% as gastroenterology, fertility, and ENT practices faced steep valuations and limited buyer appetite. Conversely, skilled nursing facilities and specialty pharmacy drove growth, indicating sponsor focus on defensive, recurring-revenue healthcare services. This dispersion reveals that healthcare PE dealmaking in 2026 will be defined less by where capital remains active and more by which subsectors are entering their next consolidation cycle.
Two specific forces decelerated Q4 activity. State-level regulatory friction—particularly in California—is fundamentally reshaping how PPM transactions structure operations and ownership, adding complexity and legal uncertainty to deals. Simultaneously, uncertainty surrounding 2026 premium subsidies created deal timing risk, causing sponsors to delay closures pending clarity. These headwinds are temporary rather than structural.
A critical recovery signal emerged: PPM exit count jumped 57.1% in 2025, suggesting sponsors are actively harvesting mature positions and repositioning capital. Combined with subsector-level divergence, this exit activity indicates that sponsor pipelines in oncology, musculoskeletal, and ambulatory surgical centers operate in fundamentally different competitive conditions than those pursuing dermatology and gastroenterology platforms. The 2026 environment will reward selectivity and regulatory nimbleness over broad-brush consolidation strategies.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.